Abstract:A lyophilized kit formulation for the efficient labelling of lipiodol with generator-produced rhenium-188 is described. The preliminary preparation of the lipophilic complex bis-(diethyldithiocarbamato)nitrido rhenium-188 (188ReN-DEDC) was carried out using a two-vial kit containing S-methyl-N-methyl-dithiocarbazate, SnCl2 and sodium oxalate in the first vial, and diethyldithiocarbamate and a carbonate buffer in the second vial. After mixing of the reaction solution with lipiodol, the complex 188ReN-DEDC was quantitatively extracted and retained by this hydrophobic substance, thus allowing the stable incorporation of the beta-emitting radionuclide. The radiochemical purity of the complex 188ReN-DEDC was 97+/-2%. The activity extracted into the lipiodol phase was 96+/-3% of the initial activity, indicating that the complex 188ReN-DEDC was almost quantitatively removed from the aqueous reaction solution. In vitro stability studies in human plasma, at 37 degrees C, demonstrated the release of less than 15% of the activity within three half-lives. The biodistribution of Re-lipiodol in non-tumour-bearing Wistar rats at 6, 24, 48 and 72 h after intraportal venous injection showed one-third of total activity in the liver at 6 h, declining to 2% retention at 72 h. Bowel uptake at 6 and 24 h declined to low levels at 48 and 72 h. Renal activity peaked at 1.7%, diminishing to 0.6% over 48 h. Rat whole body gamma imaging showed gut activity in addition to hepatic uptake at 6 and 24 h, but only liver was evident from 48 to 72 h. Kidneys were not demonstrable at any imaging time point. In nine patients, activity was localized in the tumours immediately following intrahepatic arterial injection. Computed tomography/single-photon emission computed tomography (CT/SPECT) imaging at 1 and 24 h confirmed the retention of 188Re-lipiodol in the hepatoma, with minimal gut uptake and no lung activity over 24 h. These patients were subsequently treated with activities of 2.5-5 GBq of 188Re-lipiodol fractions without adverse effects. Six patients followed for up to 2 years in the pilot study achieved stable disease and there was objective partial response in one patient. Repeated treatments were performed on two to three occasions in three patients without evident toxicity. An additional patient given 6 GBq of 188Re-lipiodol demonstrated myelosuppression, which recovered with granulocyte colony-stimulating factor (GCSF) and platelet support. It is concluded that 188Re-lipiodol, prepared using our novel kit formulation, is stable in vivo and provides safe and effective therapy of unresectable hepatocellular carcinoma when given via the hepatic artery, either alone or in combination with transarterial chemoembolization.

Evaluating the Potential of (188)Re-Ecd/lipiodol As a Therapeutic Radiopharmaceutical by Intratumoral Injection for Hepatoma Treatment.

Gd-Eob-Dtpa-Enhanced Liver Magnetic Resonance Imaging As Image Biomarker for Assessment of Liver Injury after External Beam Radiation Therapy

Magnetic Resonance Behavior of Lipiodol--an Experimental Study

Intra-arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-sponsored Multination Study.

International Atomic Energy Agency-sponsored Multination Study of Intra-Arterial Rhenium-188-labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results with Special Emphasis on Prognostic Value of Dosimetric Study.

Intratumoral injection of lipiodol pingyangmycin combined with thalidomide in treatment of recurrent advanced liver cancer

A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma

Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Liposomal Doxorubicin on Hepatocellular Carcinoma.

Evaluation of Biodistribution and Antitumor Effects of 188Re-Rhk5 in a Mouse Model of Lung Cancer

Experimental Study of Hot Lipiodol with 90 Y Intratumor Injection for Treatment of Liver Cancer

Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Imaging, Autoradiography, and Biodistribution of (188)Re-Labeled PEGylated Nanoliposome in Orthotopic Glioma Bearing Rat Model.

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 Mab and Its Efficacy Assessments by Molecular Imaging.

Ultrasound-guided Hot Lipiodol With90 Yintratumor Intra-Tumor Injectionon on Liver Cancer

Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells

Investigation of SP94 Peptide As a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Development of in situ forming thermosensitive hydrogel for radiotherapy combined with chemotherapy in a mouse model of hepatocellular carcinoma

Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma